In the fast-paced world of clinical trials, precision and efficiency are paramount. Whether you’re running a fully outsourced study or managing parts of the process internally, every decision can significantly impact trial success. One such critical decision is how to handle translations, particularly in global trials where accurate and culturally appropriate communication is non-negotiable.
The role of language in clinical trials
Language is a cornerstone in the clinical research process, especially in today’s global landscape. From patient recruitment materials to informed consent forms, from protocol documents to regulatory submissions, accurate translation ensures that these critical documents are understood correctly across diverse languages and cultures. A single mistranslation can lead to regulatory delays, misinterpretation of trial data, or worse, patient safety issues. Therefore, selecting a reliable language service provider is not just a logistical necessity; it's a strategic decision that can make or break a trial.
Fully outsourced studies: Why integrated language services matter
When sponsors choose to fully outsource their clinical studies, they gain more than just operational support. They access a seamless, end-to-end solution that includes everything from study design to regulatory approval. With language services integrated directly within a CRO’s ecosystem, sponsors are assured of a streamlined process that minimises the risks associated with external handoffs. Here’s why this matters:
- Seamless integration and communication: When language services are embedded within the same CRO supporting your trial, communication between teams is more fluid. There’s no need to juggle multiple vendors or worry about miscommunications that can occur when language services are outsourced to a third party. CRO language experts work together with clinical operations, ensuring that translations are accurate, culturally appropriate, and delivered on time.
- Quality assurance: ISO-certification guarantees that the processes meet the highest standards for quality and consistency. This is critical in maintaining the integrity trial data and ensuring compliance with regulatory requirements worldwide. Having this service in-house allows CROs to maintain strict quality control measures without relying on external providers whose standards might not align.
- Cost and time efficiency: Integrated language services can significantly reduce the time and costs associated with managing a trial. By eliminating the need for an external language provider, sponsors save on administrative costs and reduce the time lost in back-and-forth communications between multiple vendors. This efficiency can be crucial in keeping a trial on schedule and within budget.
Insourced trials: The importance of integrated language services
Even when a sponsor does not fully outsource their clinical trials to a CRO, the benefits of using integrated language services remain compelling. In scenarios where sponsors handle certain aspects of the trial themselves, translation needs often arise unexpectedly and require fast, reliable service. Here’s why integrated language services are still the best choice:
- Direct access to expert language services: Sponsors can directly engage with language services even if they’re not fully outsourcing their trial. This direct access means sponsors can still benefit from the same quality and efficiency that fully outsourced clients utilise. Whether it’s a last-minute translation request or a complex multi-language project, sponsors have the assurance that their language needs will be handled with the same rigor and quality.
- Consistency across all trial documents: When sponsors work with multiple vendors, there’s a risk of inconsistency in translations, which can lead to confusion and errors. By centralising language services within a CRO, sponsors ensure that all translations are consistent across the entire trial, reducing the risk of discrepancies that could impact data integrity or patient safety.
- Single point of accountability: With a CRO’s language services, sponsors have a single point of accountability. There’s no need to manage multiple vendors or worry about coordinating between different service providers. This simplifies the process and ensures that any issues can be quickly addressed and resolved.
- Experts everywhere you turn: With language services embedded within a CRO, you can receive a high performing translation team with experience within the localisation and pharmaceutical industries, but you also receive their colleagues. ICON’s language services are surrounded by experts in their fields, who can be directly engaged when needed.
ICON: A strategic advantage in global trials
ICON’s unique position as the only CRO with an in-house, ISO-certified language service provider offers a significant strategic advantage. In a world where clinical trials are increasingly global, the ability to ensure accurate, culturally appropriate, and compliant translations can directly impact the success of your trial. Whether you’re fully outsourcing your study to ICON or managing with a fully insourced or partial insourcing model, leveraging ICON’s integrated language services ensures you’re making the best possible choice for your trial’s success.
By choosing ICON language services you are choosing a fundamental strength that enhances the quality, efficiency, and reliability of your clinical trials.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel